Silicon Valley

In a dramatic departure from his historically cautious stance, Mike Wilson, Chief U.S. Equity Strategist at Morgan Stanley (NYSE: MS), has stunned Wall Street by raising the firm’s 12-month S&P 500...

The 7,800 Frontier: Morgan Stanley Flips the Script with Bullish S&P 500 Forecast

February 27, 2026

As of late February 2026, the financial narrative of the past two years has been dominated by a singular force in the healthcare sector: Eli Lilly & Company (NYSE: LLY). Once considered a traditional...

Topics Artificial Intelligence Economy Stocks

The Lilly Era: How Eli Lilly Transformed into a Trillion-Dollar Healthcare Titan

February 27, 2026

S&P 500 Crosses Historic 7,000 Milestone: Technical and Psychological Significance of the Breakout

Topics Artificial Intelligence ETFs

February 27, 2026

In a defining moment for global financial markets, the S&P 500 Index officially breached the 7,000-point mark for the first time in history on January 28, 2026. This monumental achievement underscores...

Though Bristol-Myers Squibb has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Topics Artificial Intelligence Economy Government

Is Bristol-Myers Squibb Stock Underperforming the Nasdaq?

February 27, 2026

Via Barchart.com

Topics Stocks

The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026

February 27, 2026

As of February 27, 2026, the narrative surrounding Novo Nordisk (NYSE: NVO) has undergone a dramatic transformation. For the better part of three years, the Danish pharmaceutical giant was the...

Via Finterra

Topics Economy Intellectual Property

OPKO Health (OPK) Q4 2025 Earnings Call Transcript ↗

February 26, 2026

OPKO Health (OPK) Q4 2025 Earnings Call Transcript

As the bull market of the mid-2020s enters a more mature and discerning phase, a profound shift is unfolding across global trading floors. The speculative fervor that once propelled "AI darlings" to...

Topics Earnings

The Great Recalibration: Investors Pivot from Silicon Dreams to Industrial Reality

February 26, 2026

The maker of Wegovy hasn't said its last words just yet.

Topics Artificial Intelligence Economy Fraud

Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play ↗

February 26, 2026

The weight-loss drug innovator is falling behind in the industry and facing major pricing pressures.

Why Shares of Novo Nordisk Stock Sank (Again) This Week ↗

February 26, 2026

Eli Lilly's New Oral Weight Loss Drug Outperforms Semaglutide, Eyes Potential US Approval In Q2 ↗

Viking Therapeutics: The High-Stakes Weight Loss Contender ↗

February 26, 2026

Via MarketBeat

February 26, 2026

Eli Lilly shares rise after orforglipron beats Novo's drug in Phase 3, cutting A1C by 2.2% and boosting weight loss results.

Via Benzinga

The Darwinian Transition: AI Monetization and Metabolic Mastery Define the Market’s New Frontier

February 26, 2026

As the final week of February 2026 draws to a close, the financial markets have emerged from what analysts are calling the most consequential “Heavyweight Week” of the post-pandemic era. The...

Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy

Topics Artificial Intelligence Economy

February 26, 2026

In a move that solidifies a new standard of care for a high-risk patient population, the U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer Inc. (NYSE: PFE) for its BRAFTOVI...

As of February 26, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at the center of one of the most polarized debates in the modern healthcare sector. Once the "poster child" of the 2024-2025...

Topics Economy Intellectual Property

Hims & Hers at the Crossroads: Navigating the ‘Regulatory Winter’ of 2026

February 26, 2026

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

Alphabet Inc. (GOOGL) Deep Dive: Navigating the Agentic Era and the $180 Billion AI Bet

February 26, 2026

As of February 26, 2026, Alphabet Inc. (NASDAQ: GOOGL) stands at a defining crossroads in its nearly three-decade history. Long the undisputed gatekeeper of the internet’s information, the Mountain...

Via Finterra

Topics Artificial Intelligence Initial Public Offering Workforce

Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore ↗

February 26, 2026

How fast can Hims & Hers grow without selling GLP-1 drugs? Maybe a lot faster than you think.

Investors are closely watching the oral GLP-1 race as competition intensifies across the sector.

Eli Lilly’s Diabetes Pill Outperforms Oral Semaglutide in Phase 3 Trial ↗

February 26, 2026

Via Stocktwits

Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow

February 25, 2026

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results this Friday morning. Here’s what you need to know.

Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies ↗

Topics Artificial Intelligence

February 25, 2026

Investors weigh steep GLP‑1 price cuts against a multibillion‑dollar oral obesity push, fresh analyst caution, and a new partnership, today, Feb. 25, 2026.

Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics

Topics Stocks

February 25, 2026

In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total...

Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. ↗

Topics Intellectual Property

February 25, 2026

Eli Lilly has seen revenue and earnings soar in recent years.

Labor Resilience Defies 'Soft Landing' Narrative: ADP Pulse Data Shows Four Weeks of Growth, Forcing Fed Rethink

February 25, 2026

The U.S. labor market is flashing a surprising signal of late-cycle strength as the shortest month of the year comes to a close. Despite a lukewarm monthly headline in early February, the latest ADP...

Although pegged as a weight-loss stock, this drug maker's core business has long been diabetes.

Topics Artificial Intelligence Economy Stocks

1 Reason Why I'd Hold This Weight‑Loss Drug Leader Through Any Market Crash ↗

February 25, 2026

Novo Nordisk now trades at just 10.6x earnings after a 58% crash, far below Eli Lilly, Vertex, and Pfizer — signaling a valuation reset.

Topics Economy

Novo Nordisk's 40% Fall May Be Creating A Deep-Value Moment ↗

February 25, 2026

Via Benzinga

Amphastar Pharmaceuticals (AMPH) Reports Earnings Tomorrow: What To Expect

February 25, 2026

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting earnings tomorrow after market hours. Here’s what to expect.

Novo, Vivtex Ink $2.1 Billion Deal To Develop Oral Medicines For Obesity And Diabetes ↗

Topics Artificial Intelligence

February 25, 2026

Novo Nordisk will lead global development, regulatory approval, manufacturing, and commercialization of the resulting products.

Via Stocktwits

Could Novo Nordisk Help Turn $100,000 Into $1 Million in the GLP‑1 Gold Rush? ↗

February 25, 2026

It would be a near-miracle gain.

Medication company Viatris (NASDAQ:VTRS) will be announcing earnings results this Thursday before market hours. Here’s what to expect.

Earnings To Watch: Viatris (VTRS) Reports Q4 Results Tomorrow

February 24, 2026

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting results this Thursday before market open. Here’s what to expect.

Topics World Trade

Collegium Pharmaceutical (COLL) Q4 Earnings: What To Expect

February 24, 2026